SCI Abstract

search
+
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study
Background: The efficacy of immune rechallenge in patients with advanced non-small cell lung cancer (NSCLC) who responded ...
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models
Ovarian cancer is the fifth leading cause of cancer related death in the United States. Cisplatin is a platinum-based anti...
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial
The reporting of adverse events (AEs) is fundamental to characterize safety profiles of novel therapeutic drug classes, ho...
Comprehensive study of gene fusions in sarcomas
Comprehensive study of gene fusions in sarcomas
Sarcomas, including bone sarcomas and soft tissue sarcomas (STSs), are a heterogeneous group of mesenchymal malignancies. ...
Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
Currently, therapeutic combinations of immune checkpoint inhibitors (ICIs) with anti-angiogenic agents have shown promisin...
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy
To extend the short half-life of fluorouracil (Fu), enhance its tumor targeting, improve efficacy, and reduce side effects...
Clinical features, treatment, and outcomes of nivolumab induced psoriasis
Clinical features, treatment, and outcomes of nivolumab induced psoriasis
Psoriasis is an uncommon immune-mediated adverse event linked to nivolumab, and its clinical characteristics remain inadeq...
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis
Melanoma, one of the most prevalent cancers worldwide, frequently metastasizes to the lung and bones. Tumor-associated mac...
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respi...
Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer
Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer
Pancreatic cancer patients urgently need new treatments, and we explored the efficacy and safety of combination therapy wi...
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA
The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-posi...
Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis
Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis
Anamorelin, a highly selective ghrelin receptor agonist, enhances appetite and increases lean body mass in patients with c...
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy
A novel molecular classification for small cell lung cancer (SCLC) has been established utilizing the transcription factor...
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
Plocabulin (Plo) induces depolymerization of tubulin fibers with disorganization and fragmentation of the microtubule netw...
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
This phase 1 first-in-human study evaluated the safety, tolerability, and pharmacokinetics of MK-1088, a novel, small-mole...
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
Background: Relugolix has been used to treat advanced prostate cancer. This study assessed adverse events (AEs) associated...
Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapies
Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapies
The therapeutic effects of many pharmacotherapies have been explored, but disadvantages such as low drug specificity, drug...
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis
Pembrolizumab has been associated with episodes of uveitis, and the clinical characteristics between them are unknown. The...
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery
Obstacles facing chemotherapeutic drugs for cancers led scientists to load Gemcitabine (GEM) into nanocarriers like liposo...
Broad-spectrum anti-cancer activity of fused human arginase variants
Broad-spectrum anti-cancer activity of fused human arginase variants
The rapid increase in cancer cases worldwide necessitates the development of novel therapeutic approaches. Therapies targe...
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer....
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Sitravatinib (MGCD516) is an oral inhibitor of several closely related oncogenic tyrosine kinase receptors that include VE...
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
Although immune checkpoint inhibitors (ICI) are used for unresectable hepatocellular carcinoma (HCC), it is unclear whethe...
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer
ESK981 is a potent tyrosine kinase and PIKfyve lipid kinase inhibitor. This phase II trial evaluated the efficacy of ESK98...
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
Combining a checkpoint inhibitor with an inhibitor of extracellular signal-regulated kinase (ERK) may result in synergisti...
Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia
Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia
Despite available treatments for acute lymphoblastic leukemia (ALL), the disease’s high clinical variability necessi...
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Gremlins, originating from early 20th-century Western folklore, are mythical creatures known for causing mechanical malfun...
Clinical research progress of fruquintinib in the treatment of malignant tumors
Clinical research progress of fruquintinib in the treatment of malignant tumors
Malignant tumors represent an important cause of mortality within the global population. Tumor angiogenesis, recognized as...
Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma
Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma
Studies have shown that the Zinc finger homeobox 4 (ZFHX4) might be a factor in the prognosis of malignancies. However, li...
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Venetoclax is a first in class BCL-2 inhibitor, currently under investigation for the treatment of t(11;14) multiple myelo...
Load More
format_indent_increase